G&S Research promotes Mike Bandick to SVP

Share this article:
Healthcare marketing research firm G&S Research promoted Mike Bandick to SVP. The move follows a company restructuring that put Bandick at the head of R&S Research's client solutions group.

George Grubb, principal of G&S Research, said in a statement that Bandick's leadership has been “instrumental in navigating the complex opportunities and recent economic contraction of the biopharmaceutical market space that we serve.”

Bandick joined R&S Research in 2006 as VP and business unit leader, and will remain a member of the company's executive committee. Prior to joining R&S Research, Bandick was senior director of marketing for Suros Surgical Systems, which was acquired by Hologic. Before that, Bandick worked in several capacities with Eli Lilly, and was most recently a global marketing director on Cymbalta, Lilly's antidepressant and pain treatment. He also worked on Zyprexa, Lilly's schizophrenia and bipolar drug. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?